VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6188)	12/31/1998 8:59:00 AM
From: David Cathcart	Read Replies (1) of 9719

Peter, You first referenced SUPG on this thread and some MOGN fans have been looking into their RFS 2000 drug, which is in P3 clinical trials for pancreatic cancer. It is a serious drug and will likely raise the bar of efficacy for pancreatic cancer with a median survival of 16.2 months among responders (33%). That easily beats Gemzar and looks like a score unless something derails it in P3. RFS 2000 is also interesting in that it is being tested on virtually the same cancers as those targeted by MOGN for MGI-114. See this graph: supergen.com The strategy of the company is virtually the same as that of MGI Pharma and their EVP & Chief Scientific Officer, Rajesh Shrotriya, M.D., once worked at MGI Pharma as Vice President and Chief Medical Officer. I like the prospects of the company and its stock looks attractive at the current market cap. I hope discussion of the company on this thread will continue. David

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next